# A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

> **NCT01224028** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 40 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01224028
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224028, "A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01224028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*